Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study-Reference-Cited by-同舟云学术

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Published:2017-03-29 Issue:1 Volume:65 Page:6-12
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Wyles David¹,Bräu Norbert²³,Kottilil Shyam⁴,Daar Eric S⁵,Ruane Peter⁶,Workowski Kimberly⁷,Luetkemeyer Anne⁸,Adeyemi Oluwatoyin⁹,Kim Arthur Y¹⁰,Doehle Brian¹¹,Huang K C¹¹,Mogalian Erik¹¹,Osinusi Anu¹¹,McNally John¹¹,Brainard Diana M¹¹,McHutchison John G¹¹,Naggie Susanna¹²,Sulkowski Mark¹³,

Affiliation:

1. Division of Infectious Diseases, Denver Health and Hospital Authority, Colorado;

2. James J. Peters Veterans Affairs Medical Center, Bronx

3. Icahn School of Medicine at Mount Sinai, New York City, New York;

4. Institute of Human Virology, University of Maryland, Baltimore;

5. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, and

6. Ruane Medical and Liver Health Institute, Los Angeles, California;

7. Emory University, Atlanta, Georgia;

8. University of California, San Francisco;

9. CORE Center, Cook County Health and Hospitals System and Rush University Medical Center, Chicago, Illinois;

10. Massachusetts General Hospital and Harvard Medical School, Boston;

11. Gilead Sciences, Foster City, California;